Fennec Pharmaceuticals Inc.
FENC
$11.29
-$0.06-0.53%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 77.83% | 72.64% | 73.84% | 78.69% | 32.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 85.18% | 72.64% | 73.84% | 78.69% | 32.91% |
| Cost of Revenue | -25.44% | 52.82% | 163.68% | -51.36% | 59.05% |
| Gross Profit | 97.50% | 73.53% | 65.56% | 110.11% | 30.52% |
| SG&A Expenses | 35.26% | 60.67% | 78.71% | 11.57% | -1.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.31% | 59.29% | 84.34% | 3.90% | 0.67% |
| Operating Income | 163.58% | 85.27% | -173.45% | 96.37% | 45.78% |
| Income Before Tax | 163.93% | 117.25% | -188.95% | 88.88% | 43.24% |
| Income Tax Expenses | -- | -- | -70.96% | -- | -- |
| Earnings from Continuing Operations | 162.60% | 117.25% | -141.16% | 88.88% | 43.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 162.60% | 117.25% | -141.16% | 88.88% | 43.24% |
| EBIT | 163.58% | 85.27% | -173.45% | 96.37% | 45.78% |
| EBITDA | 165.09% | 88.11% | -178.11% | 96.85% | 46.00% |
| EPS Basic | 150.13% | 113.98% | -112.45% | 89.07% | 44.00% |
| Normalized Basic EPS | 151.26% | 114.02% | -50.99% | 89.08% | 43.98% |
| EPS Diluted | 143.90% | 113.98% | -89.40% | 89.10% | 44.00% |
| Normalized Diluted EPS | 148.60% | 113.26% | -50.99% | 89.08% | 43.98% |
| Average Basic Shares Outstanding | 24.87% | 24.51% | 13.53% | 1.89% | 1.34% |
| Average Diluted Shares Outstanding | 31.69% | 28.90% | 13.53% | 1.89% | 1.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |